Võrdle meetodeid

	MMAT	Cochrane RoB 2.0
Valdkond	Uurimismetodoloogia	Uurimismetodoloogia
Perekond	Process / pipeline	Process / pipeline
Tekkeaasta	2014 (updated 2018)	2019
Looja	Pluye et al.	Jonathan Sterne, Julian Higgins (Cochrane Collaboration)
Tüüp	Research methodology evaluation	Clinician-rated / Research team assessment
Algallikas	Pluye, P., & Hong, Q. N. (2014). Combining the power of stories and the power of numbers: mixed methods research and mixed studies reviews. Annual Review of Public Health, 35, 29–45.	Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898.
Rööpnimetused	MMAT, MMAT 2018	RoB 2.0, RoB 2
Seotud	4	4
Kokkuvõte	MMAT (Mixed Methods Appraisal Tool) is a practical, design-agnostic quality assessment tool developed by Pluye et al. (2014, updated 2018) to evaluate the methodological quality of quantitative (RCTs, non-randomized studies), qualitative, and mixed-methods studies. Unlike tools designed for single paradigms (e.g., Cochrane RoB 2 for RCTs), MMAT provides unified criteria applicable across diverse research methodologies, making it particularly useful for systematic reviews incorporating multiple study designs.	RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias.